Table 3.

Associations between ALC, NLR, their trends and progression-free-survival (PFS) or overall survival (OS) among patients used Eribulin using multivariate cox proportional-hazards analysis

	PFSa		OSa
	HR (95%CI)	p	HR (95%CI)	p
ALC level (Low vs.High [ref]) b
At baseline	1.05 (0.53 – 2.08)	0.888	2.89 (1.33 – 6.26)	0.007*
At 1-month-testc	2.26 (1.12 – 4.55)	0.023*	1.33 (0.63 – 2.83)	0.462
At 3-month-testc	-	-	2.30 (1.03 – 5.11)	0.042*
At 6-month-testc	-	-	1.14 (0.54 – 2.40)	0.728
ALC trends (Decreasing vs. Non-decreasing[ref])
1-month-test compared with the baselined,c	0.82 (0.38 – 1.75)	0.608	0.88 (0.38 – 2.04)	0.768
3-month-test compared with the baselined,c	-	-	2.08 (0.88 – 4.94)	0.095
6-month-test compared with the baselined,c	-	-	0.76 (0.34 – 1.73)	0.515
NLR level (High vs. Low[ref])e
At baseline	0.98 (0.50 – 1.91)	0.944	1.59 (0.74 – 3.43)	0.240
At 1-month-testc	1.97 (0.96 – 4.27)	0.087	1.45 (0.67 – 3.14)	0.344
At 3-month-testc	-	-	2.37 (1.07 – 5.24)	0.033*
At 6-month-testc	-	-	2.06 (0.85 – 5.00)	0.109
NLR trends (Non-decreasing vs. non-decreasing [ref])
1-month-test compared with the baselinef,c	2.18 (0.92 – 5.18)	0.078	2.15 (0.86 – 5.39)	0.103
3-month-test compared with the baselinefc	-	-	2.50 (0.92 – 6.85)	0.074
6-month-test compared with the baselinef,c	-	-	6.12 (1.83 – 20.45)	0.003*

HR Hazard ratio, CI Confidence interval, ALC Absolute lymphocyte count, PFS Progression-free-survival, OS Overall survival

^aAdjusted for the factors have p≤0.15 in the univariate analysis above (number of metastatic sites for PFS; number of metastatic sites, eribulin line of treatment and age for OS).

^bALC high: ≥1000/µl, low: <1000/µl

^*p<0.05

^cAdditionally, model was adjusted for off/on eribulin treatment at time point corresponding with the tests

^dAdditionally, model was adjusted for ALC at baseline

^eNLR high: ≥3, low: <3

^fAdditionally, model was adjusted for NLR at baseline